Simcyp Limited today announces the appointment of Professor Carl Peck to the Simcyp Scientific Advisory Board. Professor Peck is the founding Director of the Center for Drug Development Science at UCSF, a former Director of the US FDA Center for Drug Evaluation and Research, and a former Assistant Surgeon General of the United States. He takes up his appointment with immediate effect.
Professor Peck’s research interests centre on optimising the informative value, efficiency, speed and economy of drug development and regulation using advanced concepts and techniques of clinical pharmacology, trial designs, and pharmacostatistical modelling and simulation. These interests align with Simcyp, a leader in population-based pharmacokinetic modelling and simulation.
Commenting on the appointment, Professor Peck said:
“Becoming a member of the Simcyp Scientific Advisory Board matches my long championship of in silico predictive methods in drug development and regulation. I am thrilled to join the Simcyp team and expect to add clinical and regulatory perspectives to advance Simcyp’s activities.”
The Simcyp Population-based ADME Simulator is an advanced platform for modelling and simulation of drug absorption, distribution, metabolism and elimination (ADME) in virtual populations using routinely generated in vitro data. The Simulator is licensed to members of the Simcyp Consortium, which includes 9 of the top 10 pharmaceutical companies worldwide. Scientific development at Simcyp is guided by the Simcyp Consortium and the Scientific Advisory Board, ensuring that Simcyp’s products and services meet and exceed industry need.
Commenting on the appointment, Professor Geoff Tucker, Chairman of Simcyp Limited, said:
“We are delighted that an individual of such experience is joining our Scientific Advisory Board, and we look forward to working closely with Carl as the Company develops into new areas of pharmacometrics.”